March is Colorectal Cancer Awareness Month and Now There is a New Tool to Battle the Deadly Disease
Easy-to-Use Urine-Based Diagnostic Test PolypDx™ from Atlantic Diagnostic Laboratories, Detects Precursor to Deadly Colorectal Cancer
PHILADELPHIA, March 1, 2017 /PRNewswire/ — March is Colorectal Cancer Awareness Month — to make everyone aware of the deadly disease and to remind us that regular screening saves lives. Last year colorectal cancer claimed more than 50,000 lives in the United States.
According to the American Cancer Society, the colon cancer death rate in this country could be cut in half if Americans followed recommended screening guidelines. But currently 1 in 3 adults, over age 50, are not getting tested as recommended.
Now Atlantic Diagnostic Laboratories (ADL) is making testing easier. They’ve launched PolypDx™, a non-invasive urine-based diagnostic test for detection of adenomatous polyps, the precursor to colorectal cancer. It is estimated that there will be more than 135,000 new cases reported this year. With early detection in the adenomatous polyp stage, this form of cancer is preventable. Early detection will save lives and reduce treatment costs.
“ADL is thrilled to offer this easy to use early detection test at the significantly reduced price of $199, during the month of March,” said Aaron Domenico, Chief Operating Officer of ADL. “PolypDx™ does not require any unpleasant bowel cleansing prep, nor any handling of stool required for fecal tests. Just a small urine sample is all that’s needed.”
PolypDx™ gives doctors a new tool in the prevention of colorectal cancer. In a Canadian-based clinical trial of nearly 1,000 patients, PolypDx™ demonstrated significantly higher sensitivity than current fecal-based screening tests to detect adenomatous polyps. Doctors will refer patients with a positive test to then have a colonoscopy, to remove the adenomatous polyps, preventing the progression into colorectal cancer. PolypDx™ is a simple and effective test requiring only a small urine sample.
PolypDx™ is the flagship product of Metabolomic Technologies Inc. (MTI), a privately held Canadian company based in Edmonton, Alberta. MTI has signed a multi-million dollar agreement with ADL giving them the exclusive licensing and distribution rights to bring PolypDx™ into the US market.
ADL is a full service clinical laboratory with headquarters in the suburbs of Philadelphia providing microbiology, chemistry, toxicology, immunology, virology and molecular testing in 12 states: Pennsylvania, New Jersey, Connecticut, New York, District of Columbia, Delaware, Maryland, Virginia, Florida, Ohio, Kentucky and West Virginia.
About Atlantic Diagnostic Laboratories, LLC (ADL):
Atlantic Diagnostic Laboratories, LLC (ADL) is a U.S.-based independent full service clinical laboratory providing microbiology, chemistry, toxicology, immunology, and virology testing used by the medical profession in routine testing, patient diagnosis, and in the monitoring and treatment of diseases. It has also developed niche operations based on certain types of specialized testing capabilities providing insights that empower and enable medical professionals to make better healthcare decisions. ADL is fully accredited by the College of American Pathologists (CAP) for clinical and forensic studies.
FOR MEMBERS OF THE PRESS
CONTACT | Lisa Johnson, email@example.com